Kendall Law Group Announces Class Action Against Repros Therapeutics, Inc.
(DALLAS) Kendall Law Group, led by a former federal judge and former US Attorney, announces that a class action against Repros Therapeutics, Inc. (NASDAQ: RPRX) was filed one week after the company suspended clinical trials for its Proellex drug. The lawsuit represents a class of investors who purchased RPRX stock between January 1, 2009 and July 31, 2009.
Repros Therapeutics is a biopharmaceutical company that focuses on the development drugs concerning reproductive disorders. On August 3, 2009, Repros announced that it was suspending the use of Proellex in clinical trials due to adverse events that were more serious than the company had previously reported. As a result of this announcement, Repros stock fell more than 48%, closing at $1.31 per share on August 3, 2009 with unusually high trading volume.
For information about your rights as a Repros Therapeutics shareholder, contact a Kendall Law Group attorney at 877-744-3728 or by email at administrator@kendalllawgroup.com . Kendall Law Group is led by a former federal judge and former U.S. Attorney. The firm has nationwide experience representing investors in securities litigation.
Kendall Law Group, LLP
3232 McKinney, Ste. 700
Dallas, TX 75204
(877) 744-3728 Toll Free
(214) 744-3000 Telephone
(214) 744-3015 Facsimile
administrator@kendalllawgroup.com
www.kendalllawgroup.com